UCB presents Phase 1b interim data for investigational MG drug cizutamig at AANEM meeting

By Public Technologies
  • UCB flagged new myasthenia gravis readouts scheduled for presentation at the 2026 AANEM meeting and the MGFA scientific session.
  • Post hoc analyses from late-stage studies indicated more patients reached minimal symptom expression on Zilbrysq or Rystiggo over extended follow-up.
  • An interim Phase 1b study of cizutamig in generalized myasthenia gravis reported early safety and efficacy signals, supporting further development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UCB SA published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk